Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em.
作者信息
Aisen Paul S
机构信息
Department of Neurosciences, UCSD, La Jolla, CA, USA.
出版信息
Alzheimers Dement. 2011 May;7(3):e48-50. doi: 10.1016/j.jalz.2010.06.006.
Abstract
摘要
相似文献
1
Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em.关于《阿尔茨海默病药物研发中的生物标志物》的评论。没有它们就不行。
Alzheimers Dement. 2011 May;7(3):e48-50. doi: 10.1016/j.jalz.2010.06.006.
2
Commentary on "Biomarkers in Alzheimer's disease drug development." The view from Alzheimer's Disease Neuroimaging Initiative.关于“阿尔茨海默病药物研发中的生物标志物”的评论。来自阿尔茨海默病神经影像学计划的观点。
Alzheimers Dement. 2011 May;7(3):e45-7. doi: 10.1016/j.jalz.2010.06.005.
3
Biomarkers in Alzheimer's disease drug development.阿尔茨海默病药物研发中的生物标志物。
Alzheimers Dement. 2011 May;7(3):e13-44. doi: 10.1016/j.jalz.2010.06.004. Epub 2011 May 6.
4
Drug discovery, development and delivery in Alzheimer's disease.阿尔茨海默病的药物发现、开发与递送
Pharm Res. 2017 Dec 29;35(1):3. doi: 10.1007/s11095-017-2329-6.
5
The need for thorough phase II studies in medicines development for Alzheimer's disease.在阿尔茨海默病药物研发中进行全面II期研究的必要性。
Alzheimers Res Ther. 2015 Oct 26;7(1):67. doi: 10.1186/s13195-015-0153-y.
6
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.阿尔茨海默病淀粉样β免疫治疗试验中的生物标志物
Neuropsychopharmacology. 2014 Jan;39(1):189-201. doi: 10.1038/npp.2013.154. Epub 2013 Jun 25.
7
Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.关于“阿尔茨海默病药物研发与血脑屏障问题”的评论。阿尔茨海默病药物：不止一道需要突破的屏障。
Alzheimers Dement. 2009 Sep;5(5):437-8. doi: 10.1016/j.jalz.2009.07.037.
8
Alzheimer's disease: new approaches to drug discovery.阿尔茨海默病：药物研发的新方法
Curr Opin Chem Biol. 2009 Jun;13(3):303-8. doi: 10.1016/j.cbpa.2009.04.619. Epub 2009 May 19.
9
Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.内皮细胞 LRP1-治疗阿尔茨海默病的潜在靶点：主题：阿尔茨海默病的药物发现、开发和递送 客座编辑：Davide Brambilla。
Pharm Res. 2017 Dec;34(12):2637-2651. doi: 10.1007/s11095-017-2267-3. Epub 2017 Sep 25.
10
Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.用于治疗阿尔茨海默病和帕金森病的纳米医学进展。
Nanomedicine (Lond). 2016 May;11(10):1267-85. doi: 10.2217/nnm-2016-0019. Epub 2016 Apr 14.
本文引用的文献
1
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.阿尔茨海默病神经影像学倡议的临床核心：进展与计划。
Alzheimers Dement. 2010 May;6(3):239-46. doi: 10.1016/j.jalz.2010.03.006.
2
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.阿尔茨海默病神经影像学倡议正电子发射断层扫描核心。
Alzheimers Dement. 2010 May;6(3):221-9. doi: 10.1016/j.jalz.2010.03.003.
3
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.阿尔茨海默病神经影像学倡议的磁共振成像核心进展更新。
Alzheimers Dement. 2010 May;6(3):212-20. doi: 10.1016/j.jalz.2010.03.004.
4
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.11C-PiB PET 评估 bapineuzumab 治疗阿尔茨海默病患者纤维状淀粉样β负荷的变化：一项 2 期、双盲、安慰剂对照、递增剂量研究。
Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.
5
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.一项在轻度至中度阿尔茨海默病中进行的 bapineuzumab 多剂量递增的 2 期临床试验。
Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.
6
Alzheimer's disease therapeutic research: the path forward.阿尔茨海默病治疗研究：前进的道路。
Alzheimers Res Ther. 2009 Jul 9;1(1):2. doi: 10.1186/alzrt2.
7
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.γ-分泌酶抑制剂可降低中枢神经系统中β-淀粉样蛋白的生成。
Ann Neurol. 2009 Jul;66(1):48-54. doi: 10.1002/ana.21623.
8
A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.一项针对轻度至中度阿尔茨海默病患者、使用3-氨基丙基膦酸酯靶向β-淀粉样蛋白的II期研究。
Neurology. 2006 Nov 28;67(10):1757-63. doi: 10.1212/01.wnl.0000244346.08950.64. Epub 2006 Nov 2.
9
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.在体内通过脑脊液测量的人类β淀粉样蛋白合成和清除率。
Nat Med. 2006 Jul;12(7):856-61. doi: 10.1038/nm1438. Epub 2006 Jun 25.
10
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.β-淀粉样蛋白免疫疗法（AN1792）对阿尔茨海默病脑容量MRI测量指标的影响。
Neurology. 2005 May 10;64(9):1563-72. doi: 10.1212/01.WNL.0000159743.08996.99.
Zotero 插件